Last reviewed · How we verify
Amodiaquine Sulfadoxine-Pyrimethamin administration
Amodiaquine Sulfadoxine-Pyrimethamin administration is a Small molecule drug developed by Institut de Recherche en Sciences de la Sante, Burkina Faso. It is currently FDA-approved.
Amodiaquine Sulfadoxine-Pyrimethamine, marketed by the Institut de Recherche en Sciences de la Sante in Burkina Faso, is a combination antimalarial drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action against malaria, a significant health issue in the region. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Amodiaquine Sulfadoxine-Pyrimethamin administration |
|---|---|
| Sponsor | Institut de Recherche en Sciences de la Sante, Burkina Faso |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amodiaquine Sulfadoxine-Pyrimethamin administration CI brief — competitive landscape report
- Amodiaquine Sulfadoxine-Pyrimethamin administration updates RSS · CI watch RSS
- Institut de Recherche en Sciences de la Sante, Burkina Faso portfolio CI